Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

In lab studies, blocking expression of gene reduces invasion of deadly brain tumor cells

21.10.2003


In July 2001, scientists at Cedars-Sinai’s Maxine Dunitz Neurosurgical Institute published their findings that one "isoform" or variant of a specific gene was significantly upregulated in high-grade, malignant brain tumors called glioblastoma multiforme (GBM). They theorized that this increased activity might be a critical step in the development, progression and spread of these highly aggressive tumors.



Now, in laboratory experiments designed to mimic the environment of a brain tumor and its abnormal influence on surrounding normal blood vessel cells, the researchers have found that by blocking the expression of this gene, laminin-8, they were able to reduce the tumor’s ability to invade neighboring tissue. The new study supports the hypothesis that laminin-8 is involved in the spread of these malignancies, and it reinforces the possibility that a therapy may be developed to arrest the tumors by targeting the gene.

In the original study, published in Cancer Research, the scientists used "gene array" technology to rapidly and efficiently analyze the expression of 11,004 genes in samples of low-grade tumors; high-grade tumors; brain tissue that had been located in close proximity to high-grade tumors; and unrelated normal brain tissue.


Two genes were consistently up-regulated in all high-grade and low-grade gliomas and in tissues adjacent to GBMs, the most aggressive gliomas. One of the genes was already known to be over-expressed in gliomas. The other was the alpha-4 chain of laminin, a gene that influences the thin "basement membrane" that lies beneath the surface layer of blood vessels.

One of the alpha-4 chain-containing laminin isoforms, laminin-9, was expressed mainly in the blood vessel walls of low-grade tumors and normal brain. Laminin-8 was expressed primarily in the vessel walls of the high-grade GBMs and the tissue adjacent to these types of tumors. There were some exceptions. In those cases, it was noted that an overexpression of laminin-8 correlated with a shorter time to tumor recurrence than when there was an overexpression of laminin-9. Overexpression of laminin-8 was, therefore, identified as a predictor of glioma recurrence and a potential target of intervention strategies.

These observations were reinforced by the new study, which used short strands of genetic code (Morpholino™ antisense oligonucleotides) to block the messenger RNA (mRNA) carrying the gene’s "instructions." As a result, the gene’s "protein product," laminin-8, was not produced and the invasiveness of glioma cells was significantly reduced.

Although antisense intervention was introduced more than two decades ago, new technology has overcome many earlier limitations. Unlike its predecessors, for example, Morpholino is stable in plasma.

New-generation antisense oligos are being used in studies to find effective medications and treatments for many disorders, including viruses and cancers. By blocking a gene’s effects in a laboratory setting, they enable scientists to study the gene, its control, and the interactions between gene products.

"Antisense technology is being refined not only for drug validation and diagnostic purposes but also for the development of future treatments for patients. It may become an effective tumor therapy because it offers efficiency, specificity and ease of delivery to tumor cells," said Keith L. Black, M.D., director of Cedars-Sinai’s Maxine Dunitz Neurosurgical Institute. Dr. Black directs the medical center’s Division of Neurosurgery and the Comprehensive Brain Tumor Program and holds the Ruth and Lawrence Harvey Chair in Neuroscience.

According to Julia Y. Ljubimova, M.D., Ph.D., research scientist at the Institute, the researchers decided not to conduct the experiments using glioma cells alone because laminin-8 appears to be produced both by glioma cells and by endothelial cells. By co-culturing glioma cells and brain endothelium, they were better able to mimic the situation as it would exist in actual patient tissue. Although scientists cannot say with certainty how laminin-8 promotes the spread of gliomas, this and previous studies suggest that it reduces cell adhesion and enhances cell migration – both in glioma cells and in adjacent vascular cells – circumstances that are necessary for local tumor invasiveness.

"Antisense oligos to laminin-8 chains significantly inhibited invasion of two different glioma cell lines in vitro," said Dr. Ljubimova. "If these laboratory studies can be translated into patient therapy, antisense oligos may slow the growth and spread of aggressive gliomas. Perhaps it will be used in combination with more traditional therapies or with other genetic targeting to prolong disease-free periods and increase survival."

The study was supported by a grant from the Maxine Dunitz Neurosurgical Institute. It was conducted by scientists from the Institute, the Ophthalmology Research Laboratories at Cedars-Sinai, Osaka (Japan) University Medical Center, the Interdisciplinary Center for Clinical Research at the University of Erlangen-Nuremberg (Germany), and the Institute of Biomedicine/Anatomy at the University of Helsinki (Finland).


Cedars-Sinai is one of the largest nonprofit academic medical centers in the Western United States. For the fifth straight two-year period, it has been named Southern California’s gold standard in health care in an independent survey. Cedars-Sinai is internationally renowned for its diagnostic and treatment capabilities and its broad spectrum of programs and services, as well as breakthroughs in biomedical research and superlative medical education. It ranks among the top 10 non-university hospitals in the nation for its research activities.

Sandra Van | Van Communications
Further information:
http://www.csmc.edu/

More articles from Health and Medicine:

nachricht Researchers release the brakes on the immune system
18.10.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

nachricht Norovirus evades immune system by hiding out in rare gut cells
12.10.2017 | University of Pennsylvania School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

 
Latest News

Terahertz spectroscopy goes nano

20.10.2017 | Information Technology

Strange but true: Turning a material upside down can sometimes make it softer

20.10.2017 | Materials Sciences

NRL clarifies valley polarization for electronic and optoelectronic technologies

20.10.2017 | Interdisciplinary Research

VideoLinks
B2B-VideoLinks
More VideoLinks >>>